Industry Context — Common BS Fingerprints in Medical Devices, Pharma & Biotech
Organovo, Inc.
(https://organovo.com) 📸 Data Snapshot: May 25, 2026Analyze the raw signals below. How would a machine score this business’s credibility?
Here are the exact signals captured from up to six pages of the site — the same raw inputs the evaluation engine analyzed. They are grouped by signal type so you can weigh each the way the machine does.
🏗️ Semantic Structure — heading hierarchy & page identity (Info Density · Commodity Fingerprint)
HOMEPAGE Home – Organovo, Inc. (https://organovo.com)
Home – Organovo, Inc.
NAV_HEADER_REPEATED_BODY About – Organovo, Inc. (https://organovo.com/about/)
About – Organovo, Inc.
NAV_HEADER_REPEATED_BODY Pipeline – Organovo, Inc. (https://organovo.com/pipeline/)
Pipeline – Organovo, Inc.
NAV_HEADER_HEADING_REPEATED_BODY News & Events – Organovo, Inc. (https://organovo.com/news-events/)
News & Events – Organovo, Inc.
📝 The Narrative — clean text per page (Info Density · Semantic Coherence)
HOMEPAGE · THIN (https://organovo.com) Home – Organovo, Inc.
[H1] Pioneering 3D Human Tissues for Drug Discovery [IMG: News Icon] [H2] News Apr 23 | 2025 [H3] VivoSim to Carry Forward Organovo 3D Bioprinting Read More »Apr 02 | 2025 [H3] Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements Read More »Mar 27 | 2025 [H3] Organovo Provides Business Update Read More »
SUB-PAGE · THIN (https://organovo.com/about/) About – Organovo, Inc.
[IMG: logo] About Our Story Who We Are Leadership Team Board of Directors Pipeline Overview Publications News & Events Media Coverage Careers Contact
SUB-PAGE (https://organovo.com/pipeline/) Pipeline – Organovo, Inc.
[H2] We Are Focused on the Rapid Clinical and Commercial Development of New Medicines Based on Our Exceptional 3D Human Tissue Model Technology. Organovo Has FDA Approval for FXR314 for Phase 2 Clinical Trial in Ulcerative Colitis Organovo has an FDA clinical trial authorization for a Phase 2 trial in ulcerative colitis for its lead therapeutic molecule FXR314. We have advanced our proprietary 3D human tissue models to support the most effective clinical development strategy for FXR314 and the treatment of inflammatory bowel diseases including Crohn’s Disease. FXR314 also has potential applications in the treatment of metabolic disease and oncology. FXR314, has shown, in initial clinical trials, to be a possible best-in-class FXR agonist that is delivered orally, with high potency, safety, tolerability and the potential to avoid dose-limiting toxicity issues found in other FXR targeted compounds. FXR314 has received FDA clinical trial authorization for a Phase 2 trial in ulcerative colitis. Organovo is also advancing FXR314 for the treatment of other Inflammatory Bowel Diseases including Crohn’s Disease as well as diseases of the Liver including NASH and Primary Biliary Cholangitis. Organovo expects FXR314 to have a widening set of therapeutic applications as we advance our knowledge and our science. In addition to FXR314, Organovo is planning to begin medicinal chemistry in 2023 to create a novel drug for another, as yet undisclosed, target. The target was validated in our 3d tissue models of Crohn’s disease. We expect the drug created to have an IND by the end of 2025. ProgramIndicationDiscoveryPhase 1Phase 2/3Areas of Clinical Focus FXR314Inflammatory Bowel Disease Ulcerative Colitis Novel Drug to Undisclosed TargetInflammatory Bowel DiseaseIND Expected 2025 Crohn’s Disease FXR314Liver FibrosisPhase 2 Ready. Seeking Development Partner NASH & Primary Biliary CholangitisDiscoveryPhase 1Phase 2/3 FXR314 — Inflammatory Bowel Disease Areas of Clinical Focus: Ulcerative Colitis Novel Drug to Undisclosed Target — Inflammatory Bowel DiseaseIND Expected 2025 Areas of Clinical Focus: Crohn’s Disease FXR314 — Liver FibrosisPhase 2 Ready. Seeking Development Partner Areas of Clinical Focus: NASH & Primary Biliary Cholangitis
SUB-PAGE · THIN (https://organovo.com/news-events/) News & Events – Organovo, Inc.
[H2] Upcoming Events There are no upcoming events at this time [H2] Recent Press Releases Apr 23, 2025 [H3] VivoSim to Carry Forward Organovo 3D Bioprinting Apr 02, 2025 [H3] Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements [H2] Recent Media May 6, 2019 [H3] Organovo: Bioprinting Could be the New Solution to Organ Transplantation Oct 19, 2018 [H3] 3D Method Uses Patients' Own Cells to Repair Tissue Damage
🛡️ Trust Signals — reviews, proof links, trust-theatre flag (Trust & Proof)
| Page | Reviews | Proof links |
|---|---|---|
| / (home) | 2 | 0 |
| /about/ | 2 | 0 |
| /pipeline/ | 2 | 0 |
| /news-events/ | 2 | 0 |
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps (Identity & Authority)
Homepage schema
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://organovo.com/",
"url": "https://organovo.com/",
"name": "Home - Organovo, Inc.",
"isPartOf": {
"@id": "https://organovo.com/#website"
},
"datePublished": "2019-01-10T20:36:53+00:00",
"dateModified": "2019-04-01T23:02:20+00:00",
"breadcrumb": {
"@id": "https://organovo.com/#breadcrumb"
},
"inLanguage": "en-US",
"potentialAction": [
{
"@type": "ReadAction",
"target": [
"https://organovo.com/"
]
}
]
},
{
"@type": "BreadcrumbList",
"@id": "https://organovo.com/#breadcrumb",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home"
}
]
},
{
"@type": "WebSite",
"@id": "https://organovo.com/#website",
"url": "https://organovo.com/",
"name": "Organovo, Inc.",
"description": "Pioneering 3D Human Tissues for Drug Discovery",
"potentialAction": [
{
"@type": "SearchAction",
"target": {
"@type": "EntryPoint",
"urlTemplate": "https://organovo.com/?s={search_term_string}"
},
"query-input": {
"@type": "PropertyValueSpecification",
"valueRequired": true,
"valueName": "search_term_string"
}
}
],
"inLanguage": "en-US"
}
]
}
/about/
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://organovo.com/about/",
"url": "https://organovo.com/about/",
"name": "About - Organovo, Inc.",
"isPartOf": {
"@id": "https://organovo.com/#website"
},
"primaryImageOfPage": {
"@id": "https://organovo.com/about/#primaryimage"
},
"image": {
"@id": "https://organovo.com/about/#primaryimage"
},
"thumbnailUrl": "https://organovo.com/wp-content/uploads/2019/01/orgonovo-header-about.jpg",
"datePublished": "2019-01-25T00:06:29+00:00",
"dateModified": "2023-11-10T00:22:55+00:00",
"breadcrumb": {
"@id": "https://organovo.com/about/#breadcrumb"
},
"inLanguage": "en-US",
"potentialAction": [
{
"@type": "ReadAction",
"target": [
"https://organovo.com/about/"
]
}
]
},
{
"@type": "ImageObject",
"inLanguage": "en-US",
"@id": "https://organovo.com/about/#primaryimage",
"url": "https://organovo.com/wp-content/uploads/2019/01/orgonovo-header-about.jpg",
"contentUrl": "https://organovo.com/wp-content/uploads/2019/01/orgonovo-header-about.jpg",
"width": 3840,
"height": 260,
"caption": "orgonovo-header-about"
},
{
"@type": "BreadcrumbList",
"@id": "https://organovo.com/about/#breadcrumb",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://organovo.com/"
},
{
"@type": "ListItem",
"position": 2,
"name": "About"
}
]
},
{
"@type": "WebSite",
"@id": "https://organovo.com/#website",
"url": "https://organovo.com/",
"name": "Organovo, Inc.",
"description": "Pioneering 3D Human Tissues for Drug Discovery",
"potentialAction": [
{
"@type": "SearchAction",
"target": {
"@type": "EntryPoint",
"urlTemplate": "https://organovo.com/?s={search_term_string}"
},
"query-input": {
"@type": "PropertyValueSpecification",
"valueRequired": true,
"valueName": "search_term_string"
}
}
],
"inLanguage": "en-US"
}
]
}
/pipeline/
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://organovo.com/pipeline/",
"url": "https://organovo.com/pipeline/",
"name": "Pipeline - Organovo, Inc.",
"isPartOf": {
"@id": "https://organovo.com/#website"
},
"primaryImageOfPage": {
"@id": "https://organovo.com/pipeline/#primaryimage"
},
"image": {
"@id": "https://organovo.com/pipeline/#primaryimage"
},
"thumbnailUrl": "https://organovo.com/wp-content/uploads/2019/01/orgonovo-header-pipeline-1.jpg",
"datePublished": "2019-01-10T20:37:40+00:00",
"dateModified": "2023-09-15T23:07:55+00:00",
"breadcrumb": {
"@id": "https://organovo.com/pipeline/#breadcrumb"
},
"inLanguage": "en-US",
"potentialAction": [
{
"@type": "ReadAction",
"target": [
"https://organovo.com/pipeline/"
]
}
]
},
{
"@type": "ImageObject",
"inLanguage": "en-US",
"@id": "https://organovo.com/pipeline/#primaryimage",
"url": "https://organovo.com/wp-content/uploads/2019/01/orgonovo-header-pipeline-1.jpg",
"contentUrl": "https://organovo.com/wp-content/uploads/2019/01/orgonovo-header-pipeline-1.jpg",
"width": 3840,
"height": 260,
"caption": "orgonovo-header-pipeline"
},
{
"@type": "BreadcrumbList",
"@id": "https://organovo.com/pipeline/#breadcrumb",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://organovo.com/"
},
{
"@type": "ListItem",
"position": 2,
"name": "Pipeline"
}
]
},
{
"@type": "WebSite",
"@id": "https://organovo.com/#website",
"url": "https://organovo.com/",
"name": "Organovo, Inc.",
"description": "Pioneering 3D Human Tissues for Drug Discovery",
"potentialAction": [
{
"@type": "SearchAction",
"target": {
"@type": "EntryPoint",
"urlTemplate": "https://organovo.com/?s={search_term_string}"
},
"query-input": {
"@type": "PropertyValueSpecification",
"valueRequired": true,
"valueName": "search_term_string"
}
}
],
"inLanguage": "en-US"
}
]
}
/news-events/
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://organovo.com/news-events/",
"url": "https://organovo.com/news-events/",
"name": "News & Events - Organovo, Inc.",
"isPartOf": {
"@id": "https://organovo.com/#website"
},
"primaryImageOfPage": {
"@id": "https://organovo.com/news-events/#primaryimage"
},
"image": {
"@id": "https://organovo.com/news-events/#primaryimage"
},
"thumbnailUrl": "https://organovo.com/wp-content/uploads/2019/01/orgonovo-header-news-events.jpg",
"datePublished": "2019-01-10T20:38:05+00:00",
"dateModified": "2019-05-30T22:30:35+00:00",
"breadcrumb": {
"@id": "https://organovo.com/news-events/#breadcrumb"
},
"inLanguage": "en-US",
"potentialAction": [
{
"@type": "ReadAction",
"target": [
"https://organovo.com/news-events/"
]
}
]
},
{
"@type": "ImageObject",
"inLanguage": "en-US",
"@id": "https://organovo.com/news-events/#primaryimage",
"url": "https://organovo.com/wp-content/uploads/2019/01/orgonovo-header-news-events.jpg",
"contentUrl": "https://organovo.com/wp-content/uploads/2019/01/orgonovo-header-news-events.jpg",
"width": 3840,
"height": 260,
"caption": "orgonovo-header-news-events"
},
{
"@type": "BreadcrumbList",
"@id": "https://organovo.com/news-events/#breadcrumb",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://organovo.com/"
},
{
"@type": "ListItem",
"position": 2,
"name": "News & Events"
}
]
},
{
"@type": "WebSite",
"@id": "https://organovo.com/#website",
"url": "https://organovo.com/",
"name": "Organovo, Inc.",
"description": "Pioneering 3D Human Tissues for Drug Discovery",
"potentialAction": [
{
"@type": "SearchAction",
"target": {
"@type": "EntryPoint",
"urlTemplate": "https://organovo.com/?s={search_term_string}"
},
"query-input": {
"@type": "PropertyValueSpecification",
"valueRequired": true,
"valueName": "search_term_string"
}
}
],
"inLanguage": "en-US"
}
]
}
Your Diagnosis
Before revealing the machine’s verdict, predict the BS score for each signal. Higher = more BS (more fluff, less verifiable substance). Drag each slider, then submit to compare your judgment against the engine.
Stuck? Reveal the heuristic lens — how the deterministic page-auditor reads each signal (no AI, pure pattern rules)
These are the structural rules a local, deterministic auditor applies — the same lens you can use to judge each signal. They describe what to look for, not this company’s result.
Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.
Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.
Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.
Look at how much sentence length varies. Natural writing varies its rhythm; templated or mass-produced copy is statistically uniform. Very low variation reads as commodity content — unless unique named entities break the pattern.
Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.
Want to apply this lens yourself? The free BS Indicator Chrome extension runs these heuristic checks live on any page. Bear in mind it is a single-page, deterministic tool — it relies only on pattern rules for the page in front of it and does not perform the cross-page semantic correlation this audit uses, so its readout is a starting lens, not the full verdict.
Based on 784 businesses audited.
Medical Devices, Pharma & Biotech BS: Organovo, Inc. (organovo.com)
Organovo presents a classic Biotech time-capsule: high technical promise and specific pipeline terminology undermined by a total lack of updated evidence and technical schema. The gap between its 2025 milestones and the current 2026 date suggests a company whose digital presence has stalled while its Nasdaq status remains under pressure.
Immediately update the Pipeline page to reflect the actual status of the 2025 IND goal. Replace the simulated review_count of 2 with direct outbound links to peer-reviewed publications or ClinicalTrials.gov identifiers. Populate the About page with actual body text and executive bios rather than just navigation links. Implement Organization and Person schema to link the company and leadership to verifiable external databases.
The site content strongly aligns with the Pharma & Biotech industry, specifically focusing on 3D bioprinting and therapeutic pipeline development for inflammatory bowel diseases. The mention of Nasdaq listing requirements and FDA clinical trial authorizations confirms this is a high-stakes regulated entity.
“The score of 51 is primarily driven by Trust and Proof failures (specifically the 0 proof links vs 2 reviews) and Identity/Authority gaps in the technical implementation. While the Pipeline substance is superior to generic marketing sites, the temporal decay (unmet 2025 milestones) and the hollow About page prevent a lower BS score.”
This training module utilizes a snapshot of public data from Organovo, Inc., captured on May 25, 2026, to demonstrate how machine logic evaluates different types of business narratives.
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to compare human intuition against machine-generated evaluations.
Notice to Organovo, Inc.: This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results provided by 1EuroSEO are intended as professional feedback to help improve any website’s machine-readability and authority signals. The 1EuroSEO BS Detection Tool is a free tool, and anyone can test any company to see how their content is interpreted by AI models.
Any company can use the insights for free and improve its voice by comparing it to industry clichés or competitors. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://organovo.com to view the most current version of its content and learn from the source what this company is about and what it offers.